What explains the sharp drop in revenue costs in 2024?

The sharp drop in revenue costs in 2024 can be attributed to several factors: 1. **Strategic Alternatives Exploration**: Portage Biotech is exploring strategic alternatives, which may include finding a partner for its assets, a sale of the company, or a merger. This strategic shift could lead to a reduction in revenue costs as the company focuses on optimizing its resources. 2. **Prioritization of Clinical Trials**: Lexicon Pharmaceuticals has prioritized its clinical development pipeline, particularly focusing on high-potential programs. This prioritization could lead to a reduction in revenue costs associated with less promising projects. In summary, the sharp drop in revenue costs in 2024 is primarily driven by strategic adjustments and prioritization of clinical trials by Portage Biotech and Lexicon Pharmaceuticals, respectively.